Retinoic acid primes human dendritic cells to induce gut-homing, IL-10-producing regulatory T cells

G Bakdash, L T C Vogelpoel, T M M van Capel, M L Kapsenberg, E C de Jong, G Bakdash, L T C Vogelpoel, T M M van Capel, M L Kapsenberg, E C de Jong

Abstract

The vitamin A metabolite all-trans retinoic acid (RA) is an important determinant of intestinal immunity. RA primes dendritic cells (DCs) to express CD103 and produce RA themselves, which induces the gut-homing receptors α4β7 and CCR9 on T cells and amplifies transforming growth factor (TGF)-β-mediated development of Foxp3(+) regulatory T (Treg) cells. Here we investigated the effect of RA on human DCs and subsequent development of T cells. We report a novel role of RA in immune regulation by showing that RA-conditioned human DCs did not substantially enhance Foxp3 but induced α4β7(+) CCR9(+) T cells expressing high levels of interleukin (IL)-10, which were functional suppressive Treg cells. IL-10 production was dependent on DC-derived RA and was maintained when DCs were stimulated with toll-like receptor ligands. Furthermore, the presence of TGF-β during RA-DC-driven T-cell priming favored the induction of Foxp3(+) Treg cells over IL-10(+) Treg cells. Experiments with naive CD4(+) T cells stimulated by anti-CD3 and anti-CD28 antibodies in the absence of DCs emphasized that RA induces IL-10 in face of inflammatory mediators. The data thus show for the first time that RA induces IL-10-producing Treg cells and postulates a novel mechanism for IL-10 in maintaining tolerance to the intestinal microbiome.

References

    1. Front Immunol. 2012 Feb 29;3:30
    1. J Immunol. 2007 Sep 15;179(6):3724-33
    1. Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1687-92
    1. N Engl J Med. 2009 Nov 19;361(21):2033-45
    1. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):770-4
    1. Curr Opin Pediatr. 2001 Dec;13(6):533-8
    1. Biochem J. 1930;24(3):692-702
    1. J Immunol. 1998 Aug 15;161(4):1664-70
    1. J Immunol. 2005 May 15;174(10):5950-8
    1. Infect Immun. 1998 Nov;66(11):5224-31
    1. FEMS Immunol Med Microbiol. 2006 Aug;47(3):444-50
    1. Gastroenterology. 2011 Nov;141(5):1802-12
    1. J Exp Med. 1989 Dec 1;170(6):2081-95
    1. Leuk Res. 2010 Apr;34(4):513-20
    1. Nature. 1992 Oct 22;359(6397):693-9
    1. J Exp Med. 2002 Jun 3;195(11):1499-505
    1. Cancer Res. 1998 Jul 15;58(14):3163-72
    1. J Pharmacol Exp Ther. 2000 Dec;295(3):979-85
    1. Immunity. 2009 Sep 18;31(3):502-12
    1. Immunity. 2009 Aug 21;31(2):209-19
    1. Gastroenterology. 2011 Nov;141(5):1813-20
    1. J Exp Med. 1998 Feb 16;187(4):571-8
    1. J Exp Med. 2007 Aug 6;204(8):1775-85
    1. Immunity. 2004 Oct;21(4):527-38
    1. J Exp Med. 2008 Sep 1;205(9):2139-49
    1. J Immunol. 2008 Sep 15;181(6):3745-9
    1. Nat Immunol. 2007 Dec;8(12):1390-7
    1. Immunity. 2011 Jul 22;35(1):13-22
    1. J Immunol. 2009 Sep 15;183(6):4119-26
    1. Cytokine Growth Factor Rev. 2010 Oct;21(5):331-44
    1. J Immunol. 2011 Jan 15;186(2):733-44
    1. Cell. 1993 Oct 22;75(2):263-74
    1. J Exp Med. 2007 Aug 6;204(8):1765-74
    1. Int Immunol. 2009 Apr;21(4):361-77
    1. Curr Opin Gastroenterol. 2008 Nov;24(6):733-41
    1. J Exp Med. 2004 Nov 15;200(10):1289-97
    1. J Immunol. 2010 Nov 15;185(10):5915-25
    1. J Immunol. 2002 Feb 15;168(4):1704-9
    1. J Exp Med. 2009 Feb 16;206(2):343-57
    1. J Exp Med. 2007 Feb 19;204(2):273-83
    1. Gut. 2009 Nov;58(11):1481-9
    1. J Allergy Clin Immunol. 2011 Jun;127(6):1532-40.e7
    1. Science. 2007 Jul 13;317(5835):256-60
    1. Gastroenterology. 2011 Dec;141(6):2109-18
    1. BMC Immunol. 2006 Nov 21;7:27
    1. Immunity. 2011 Apr 22;34(4):554-65
    1. J Exp Med. 2007 Aug 6;204(8):1757-64
    1. Gastroenterology. 2011 Jul;141(1):176-85
    1. Mucosal Immunol. 2011 Jul;4(4):438-47
    1. J Biomed Sci. 2009 Feb 12;16:20
    1. Nat Genet. 2008 Nov;40(11):1319-23
    1. Immunol Rev. 2001 Aug;182:68-79

Source: PubMed

3
Iratkozz fel